PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023
21 Dicembre 2023 - 2:00PM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"),
an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals, achieved a significant milestone –
surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology
distributed to veterinarians in the 2023 calendar year. Thanks to
the support of veterinarians throughout the United States, Spryng
has experienced strong momentum this year, driven by the beneficial
outcomes experienced by thousands of animals injected with this
life changing product.
“Achieving this distribution milestone involving
Spryng is a testament to the unwavering support of the veterinarian
community and their passion to help animals suffering from
debilitating lameness related diseases, such as osteoarthritis,”
said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
“We’re grateful for all the veterinarians who have added Spryng to
their toolbox of therapeutics and medical devices, and we’re
thrilled that we are witnessing the positive impact Spryng has had
in helping animals suffering from joint related afflictions.”
Veterinarian enthusiasm for Spryng is higher
than ever making this the biggest year yet for Spryng distribution.
The distribution of syringes of Spryng is an increase in excess of
sixty percent from the previous year. This momentum has been driven
by the release of recent Spryng clinical study data, such as a
cranial cruciate disease study performed by Ethos Veterinary
Health, as well as numerous presentations and references at
industry trade shows by reputable key opinion leaders in the equine
and small animal veterinary community. We anticipate this
enthusiasm will magnify into the new year with the release of
additional clinical studies and exposure at small animal veterinary
trade shows, including the Veterinary Medical Expo in Orlando
Florida in January, 2024 and the Western Veterinary Conference in
Las Vegas, Nevada in February, 2024.
SPRYNG™ with OsteoCushion™ Technology, is an
intra-articular injectable veterinary medical device consisting of
sterilized, extra-cellular matrix microparticles. The
microparticles of Spryng have been found to adsorb onto the joint
synovial lining of animals and subsequently integrate with the
animal’s subsynovial tissue. Such action promotes the restoration
of proper joint mechanics, thereby aiding in the management of
noninfectious sources of joint pain such as joint instability,
degenerative joint disease and osteoarthritis.
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty patents
protects the Company's biomaterials, products, production processes
and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint-related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:
John Lai, CEO PetVivo Holdings, Inc. Email:
info1@petvivo.com (952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2023 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Grafico Azioni PetVivo (NASDAQ:PETVW)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni PetVivo (NASDAQ:PETVW)
Storico
Da Set 2023 a Set 2024